PolyPid (PYPD) Profit After Tax (2019 - 2026)
PolyPid (PYPD) posted Profit After Tax of $7.7 million for Q1 2026, up 112.91% sequentially from -$59.9 million in Q4 2025, and down 6.53% YoY from $8.3 million in Q1 2025.
PolyPid (PYPD) Profit After Tax (2019 - 2026) Analysis & Trends
PolyPid has reported Profit After Tax for 8 years, with the latest figure at $7.7 million in Q1 2026.
- Quarterly Profit After Tax fell 6.53% year-over-year to $7.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$34.7 million (down 27.6% YoY) and the FY2025 annual result came in at -$34.2 million, down 17.73% from the prior year.
- Profit After Tax advanced to $7.7 million in Q1 2026 per PYPD's latest filing, from -$59.9 million in the prior quarter.
- Over five years, Profit After Tax peaked at $11.9 million in Q1 2022 and troughed at -$59.9 million in Q4 2025.
- A 5-year average of $468176.5 and a median of $6.6 million in 2022 frame the typical range for Profit After Tax.
- The sharpest annual moves came in 2022 and 2024: Profit After Tax jumped 2526382878.72% in 2022, then tumbled 879.17% in 2024.
- Over 5 years, Profit After Tax stood at $6.6 million in 2022, then declined by 3.21% to $6.4 million in 2023, then sank by 879.17% to -$49.5 million in 2024, then decreased by 20.88% to -$59.9 million in 2025, then jumped by 112.91% to $7.7 million in 2026.
- According to Business Quant data, Profit After Tax over the past three periods registered $7.7 million, -$59.9 million, and $7.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 472.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 164.49 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -16.62 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 81.49 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -355.03 Mn |
| 10 | PolyPid | 113.30 Mn | 106.53 Mn | - | 7.85 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -23.30 Mn |
| Mar 31, 2026 | 7.73 Mn |
| Dec 31, 2025 | -59.87 Mn |
| Sep 30, 2025 | 7.45 Mn |
| Jun 30, 2025 | 9.98 Mn |
| Mar 31, 2025 | 8.27 Mn |
| Dec 31, 2024 | -49.52 Mn |
| Sep 30, 2024 | 7.76 Mn |
| Jun 30, 2024 | 6.29 Mn |
| Mar 31, 2024 | 6.45 Mn |
| Dec 31, 2023 | 6.36 Mn |
| Sep 30, 2023 | 5.60 Mn |
| Jun 30, 2023 | 5.84 Mn |
| Mar 31, 2023 | 6.07 Mn |
| Dec 31, 2022 | 6.57 Mn |
| Sep 30, 2022 | 9.27 Mn |
| Jun 30, 2022 | 11.85 Mn |
| Mar 31, 2022 | 11.87 Mn |
| Dec 31, 2021 | 0.72 |
| Sep 30, 2021 | 9.94 Mn |